The Rise and Fall “ing” of the HDL Hypothesis

作者: Julien J. Feghaly , Arshag D. Mooradian

DOI: 10.1007/S40265-020-01265-4

关键词: Reverse cholesterol transportClinical trialPharmacotherapyCholesterylester transfer proteinMedicineNicotinic agonistEndocrinologyRandomized controlled trialDe novo synthesisInternal medicineInverse correlation

摘要: Earlier epidemiological studies have shown an inverse correlation between high-density lipoprotein cholesterol (HDLc) and coronary heart disease (CHD). This observation along with the finding that reverse transport is mediated by HDL, supported hypothesis HDL molecule has a cardioprotective role. More recently, data suggest U-shaped curve correlating HDLc CHD. In addition, randomized clinical trials of drugs significantly increase plasma levels, such as nicotinic acid ester transfer protein (CETP) inhibitors failed to show reduction in major adverse cardiovascular events. These observations challenge It possible quality function optimal only when de novo synthesis apo A-I occurs. Inhibition turnover currently available agents yields molecules are ineffective transport. To test this hypothesis, newer therapeutic production should be tested trials.

参考文章(86)
G. Kees Hovingh, Loek P. Smits, Claudia Stefanutti, Handrean Soran, See Kwok, Jacqueline de Graaf, Daniel Gaudet, Constance H. Keyserling, Heather Klepp, Jennifer Frick, John F. Paolini, Jean-Louis Dasseux, John J.P. Kastelein, Erik S. Stroes, The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study American Heart Journal. ,vol. 169, pp. 736- 742 ,(2015) , 10.1016/J.AHJ.2015.01.008
Dana Bailey, Ravi Jahagirdar, Allan Gordon, Anouar Hafiane, Steven Campbell, Safia Chatur, Gregory S. Wagner, Henrik C. Hansen, Fabrizio S. Chiacchia, Jan Johansson, Larbi Krimbou, Norman C.W. Wong, Jacques Genest, RVX-208: A Small Molecule That Increases Apolipoprotein A-I and High-Density Lipoprotein Cholesterol In Vitro and In Vivo Journal of the American College of Cardiology. ,vol. 55, pp. 2580- 2589 ,(2010) , 10.1016/J.JACC.2010.02.035
ORIGIN Trial Investigators, None, n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. The New England Journal of Medicine. ,vol. 367, pp. 309- 318 ,(2012) , 10.1056/NEJMOA1203859
Arshag D. Mooradian, The Effect of Nutrients on Apolipoprotein A‐I Gene Expression High‐Density Lipoproteins. pp. 399- 423 ,(2007) , 10.1002/9783527625178.CH16
Shant Parseghian, Luisa M. Onstead-Haas, Norman C.W. Wong, Arshag D. Mooradian, Michael J. Haas, Inhibition of Apolipoprotein A-I Expression by TNF-Alpha in HepG2 Cells: Requirement for c-jun Journal of Cellular Biochemistry. ,vol. 115, pp. 253- 260 ,(2014) , 10.1002/JCB.24656
, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients New England Journal of Medicine. ,vol. 371, pp. 203- 212 ,(2014) , 10.1056/NEJMOA1300955
Joe M. Chehade, Margaret Gladysz, Arshag D. Mooradian, Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management Drugs. ,vol. 73, pp. 327- 339 ,(2013) , 10.1007/S40265-013-0023-5
Arshag D. Mooradian, Michael J. Haas, Norman C. W. Wong, The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels Endocrine Reviews. ,vol. 27, pp. 2- 16 ,(2006) , 10.1210/ER.2005-0013
Sanjay Patel, Belinda A. Di Bartolo, Shirley Nakhla, Alison K. Heather, Todd W. Mitchell, Wendy Jessup, David S. Celermajer, Philip J. Barter, Kerry-Anne Rye, Anti-inflammatory effects of apolipoprotein A-I in the rabbit Atherosclerosis. ,vol. 212, pp. 392- 397 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.05.035